Treatment of Idiopathic Castleman Disease
Open Access
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 32 (1), 89-106
- https://doi.org/10.1016/j.hoc.2017.09.008
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- HHV-8–encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in miceBlood, 2012
- Surgery in Castleman's DiseaseAnnals of Surgery, 2012
- Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman diseaseBlood, 2012
- Castleman's Disease: Systematic Analysis of 416 Patients from the LiteratureThe Oncologist, 2011
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyBlood, 2010
- Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)Molecular Cancer Therapeutics, 2010
- Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case reportJournal of Hematology & Oncology, 2009
- Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomenaAmerican Journal of Hematology, 2005
- Retinoic acid for treatment of multicentric Castleman's diseaseThe Lancet, 1999
- Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.JCI Insight, 1990